Breast Cancer: Should We Assess HER2 Status by Oncotype DX?

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2011 Dec 7

PMID 22143144

Citations 6

Authors

Michail Ignatiadis

Christos Sotiriou

Affiliations

Soon will be listed here.

Citing Articles

A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2.

Jensen K, Krusenstjerna-Hafstrom R, Lohse J, Petersen K, Derand H Mod Pathol. 2016; 30(2):180-193.

PMID: 27767098 DOI: 10.1038/modpathol.2016.176.

Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.

Vincent-Salomon A, Benhamo V, Gravier E, Rigaill G, Gruel N, Robin S PLoS One. 2013; 8(10):e76496.

PMID: 24143191 PMC: 3797106. DOI: 10.1371/journal.pone.0076496.

Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling.

Chun J, Zangle T, Kolarova T, Finn R, Teitell M, Reed J Analyst. 2012; 137(23):5495-8.

PMID: 23057068 PMC: 3494737. DOI: 10.1039/c2an36058f.

Perspectives on systems biology applications in diabetic kidney disease.

Komorowsky C, Brosius 3rd F, Pennathur S, Kretzler M J Cardiovasc Transl Res. 2012; 5(4):491-508.

PMID: 22733404 PMC: 3422674. DOI: 10.1007/s12265-012-9382-7.

A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.

Nitta H, Kelly B, Padilla M, Wick N, Brunhoeber P, Bai I Diagn Pathol. 2012; 7:60.

PMID: 22647525 PMC: 3487810. DOI: 10.1186/1746-1596-7-60.

References

Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Muller B . Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Res Treat. 2010; 126(1):109-17. DOI: 10.1007/s10549-010-1316-y. View

Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K . Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002; 94(11):852-4. DOI: 10.1093/jnci/94.11.852. View

Sauter G, Lee J, Bartlett J, Slamon D, Press M . Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009; 27(8):1323-33. DOI: 10.1200/JCO.2007.14.8197. View

Dabbs D, Klein M, Mohsin S, Tubbs R, Shuai Y, Bhargava R . High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study. J Clin Oncol. 2011; 29(32):4279-85. DOI: 10.1200/JCO.2011.34.7963. View

Wolff A, Hammond M, Schwartz J, Hagerty K, Allred D, Cote R . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2006; 25(1):118-45. DOI: 10.1200/JCO.2006.09.2775. View